Tag: Novartis

Lawyers Collective Response to Testimony of Mr. Roy F Waldron, Pfizer Inc.

Recently, several multinational pharmaceutical companies along with the US Chamber of Commerce have been instrumental in mounting pressure on India to decry the alleged state of Intellectual Property (IP) regime in India. On June 27, 2013 a hearing, ‘A tangle of trade barriers’ before the US Energy and Commerce Committee...

Read More

Indian Patent Law TRIPS Compliant: Novartis judgment shows the way

While patients groups around the world have expressed joy over the Novartis decision of the Supreme Court of India, western Multi National Companies (MNCs) and their governments have expressed extreme displeasure over it. Some in the US have even urged their Administration to take India to the Dispute Panel under...

Read More

Analysing the Novartis Story

Vol – XLVIII No. 32, August 10, 2013 | Anand Grover A detailed account of the examination of Section 3(d) of the Indian Patents Act in the Supreme Court’s judgment on Novartis’s patent application for Glivec. Anand Grover (anandgrover@gmail.com) is a Senior Advocate practising in the Supreme Court and the Director of...

Read More

Why Novartis case will help innovation

The Supreme Court judgment on Glivec is a blow for a patent regime with a higher threshold of inventiveness On April 1, 2013, the Supreme Court upheld the Intellectual Property Appellate Board’s decision to deny patent protection to Novartis’s application covering a beta crystalline form of imatinib —the medicine Novartis...

Read More

India’s patent case victory rattles Big Pharma

Will India, the world’s biggest provider of low-cost generic medicines, be the pariah or the pioneer of the pharmaceutical world? There is renewed focus on this thorny question in the wake of India’s Supreme Court’s dismissal of Swiss pharma giant Novartis AG’s appeal for a patent for its cancer drug...

Read More

Novartis Ruling Reverberates Past India’s Borders

India’s Supreme Court says drug maker Novartis can’t hold onto its patent for the pricey cancer drug Gleevec simply by tweaking its chemical formula. That means generic drug makers can keep making a form of the drug at a tenth of Novartis’s price. Consumer advocates call it a major advance...

Read More

Apex court right to reject Novartis’s attempt

Novartis  threat that it would not introduce new medicines in India after the verdict is hollow, says Anand Grover. While the patients and the generic companies have rejoiced over the Supreme Court’s verdict in the Novartis case rejecting the patent for its drug Gleevec, Novartis itself has threatened that it...

Read More
Page 1 of 3123